
Publication
Securities regulators amend investment limits for offering memorandum exemption
Canadian securities regulators have made changes to give investors greater access to exempt markets.
United Kingdom | Publication | May 2023
On April 27, 2023, the Regulator published its annual funding statement for DB schemes. This statement is essential reading for trustees of schemes with valuation dates between September 22, 2022, and September 21, 2023 (known as Tranche 18, or T18).
It is also relevant to schemes undergoing significant changes that require a review of their funding and risk strategies. The Regulator recognises that this year schemes may be in a transformed funding position, and its key messages are:
The Regulator has divided the DB universe into 3 groups:
For each Group, the Regulator has set out guidance in respect of rethinking scheme strategies in relation to funding position, investment consideration, and covenant considerations. The funding statement also provides a set of tables so that trustees can match their specific scheme circumstances in terms of funding characteristics, employer strength and scheme maturity with the Regulator’s expectations. However, the Regulator stresses that the tables are inexhaustive and are no substitute for reading the funding statement and seeking specialist advice.
Our May briefing will look in more detail at the annual funding statement.
Publication
Canadian securities regulators have made changes to give investors greater access to exempt markets.
Publication
By a joint announcement on 6 May 2025, the Securities and Exchange Commission and The Stock Exchange of Hong Kong Limited launched a dedicated channel for listing applicants of Specialist Technology Companies and Biotech Companies.
Subscribe and stay up to date with the latest legal news, information and events . . .
© Norton Rose Fulbright LLP 2025